year rate of any clinical failure was 9.4 percent for men with a doubling time of more than 8 months and 60.4 percent for those with a shorter doubling time. Corresponding values for true clinical failure were 6.5 percent and 68.5 percent. For estimated 6-year overall survival after PSA failure, the proportions were 79.1 percent and 29.7 percent. These results, Lee concluded, "further define the role of using PSA doubling time in predicting which men may have worse clinical outcomes, including decreased survival, after combination treatment with radiation and hormonal therapy, and aid in the selection of patients for more rigorous monitoring and more aggressive...therapies."